BOUNDLESS BIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
BOUNDLESS BIO, INC. (BOLD) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.12 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-07
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-06-30 was $1.12, a 25.84% increase year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $1.04, a 50.24% decline year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-09-30 was $0.93, a 87.17% decline year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-06-30 was $0.89, a 80.44% decline year-over-year.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $1.88, a 73.85% decline from fiscal 2024.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $7.19, a 122.60% increase from fiscal 2023.
- BOUNDLESS BIO, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $3.23.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.12 10-Q · filed 2026-08-07 | $1.05 10-Q · filed 2026-08-07 | ||
| 2026-03-31 | $1.04 10-Q · filed 2026-05-08 | |||
| 2025-12-31 | $1.88 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $0.93 10-Q · filed 2025-11-05 | $1.88 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $0.89 10-Q · filed 2026-08-07 | $1.89 10-Q · filed 2026-08-07 | ||
| 2025-03-31 | $2.09 10-Q · filed 2026-05-08 | |||
| 2024-12-31 | $7.19 10-K · filed 2026-03-09 | |||
| 2024-09-30 | $7.25 10-Q · filed 2025-11-05 | $7.20 10-Q · filed 2025-11-05 | ||
| 2024-06-30 | $4.55 10-Q · filed 2025-08-05 | $11.59 10-Q · filed 2025-08-05 | ||
| 2024-03-31 | $11.69 10-Q · filed 2025-05-09 | |||
| 2023-12-31 | $3.23 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $3.23 10-Q · filed 2024-11-07 | $5.80 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $5.64 10-Q · filed 2024-08-12 | $5.64 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | $7.62 10-Q · filed 2024-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Rein Therapeutics, Inc. (RNTX) | United States | $0.063B | -1.76 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B |